;
Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Delenex's DLX105 misses in psoriasis Phase II

    Delenex Therapeutics AG (Zurich, Switzerland) said DLX105 led to no significant clinical improvements in a Phase II trial in mild to moderate plaque psoriasis. The co-primary efficacy endpoints were local Psoriasis Area…

    Published on 9/12/2014
  • CLINICAL NEWS: Lilly's ramucirumab meets Phase III colorectal endpoint

    Eli Lilly and Co. (NYSE:LLY) said ramucirumab plus chemotherapy increased overall survival, the primary endpoint, in a Phase III trial as second-line therapy for metastatic colorectal cancer (mCRC). The company declined…

    Published on 9/12/2014
  • CLINICAL NEWS: Tecemotide discontinued in NSCLC

    Oncothyreon Inc. (NASDAQ:ONTY) said in an SEC filing that partner Merck KGaA (Xetra:MRK) will stop development of tecemotide (L-BLP25) as a monotherapy for non-small cell lung cancer (NSCLC). The compound was in Phase …

    Published on 9/12/2014
  • CLINICAL NEWS: Bausch + Lomb option to MIM-D3 terminated

    Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) said an option was terminated Aug. 31 that would have allowed the Bausch + Lomb Inc. unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) to take …

    Published on 9/11/2014
  • CLINICAL NEWS: More RPC1063 data boosts Receptos

    Investors have added $364 million in market cap to Receptos Inc. (NASDAQ:RCPT) over the past two days after the biotech provided the first look at annualized relapse rates (ARRs) for RPC1063 in multiple sclerosis, along…

    Published on 9/11/2014
  • CLINICAL NEWS: Serono providing funding for real-world MS study

    EMD Serono Inc. is providing at least $1 million in funding to the Accelerated Cure Project (ACP) for Multiple Sclerosis for the non-profit's longitudinal U.S. study focused on obtaining real-world data from MS patients…

    Published on 9/11/2014
  • CLINICAL NEWS: First Phase III data for Mimetogen's dry eye compound

    Mimetogen Pharmaceuticals Inc. (Montreal, Quebec) reported top-line data from a Phase III trial of MIM-D3 for dry eye, but did not report data from a second endpoint listed for the study on clinicaltrials.gov.The …

    Published on 9/10/2014
  • CLINICAL NEWS: Moxifloxacin regimens miss Phase III endpoint

    The not-for-profit Global Alliance for TB Drug Development said use of moxifloxacin in combination regimens did not shorten treatment time in tuberculosis patients, compared with standard of care (SOC) regimens. In the …

    Published on 9/8/2014
  • CLINICAL NEWS: China to manufacture Ebola treatment

    China Central Television said the country approved manufacturing of selective RNA polymerase inhibitor JK-05 for emergency use to treat Ebola cases within China's People's Liberation Army.According to CCTV news, the …

    Published on 9/5/2014
  • CLINICAL NEWS: FDA lifts partial hold on OncoMed's ipafricept

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said FDA lifted a partial hold on Phase Ib trials of oncology candidate ipafricept (Fzd8-Fc, OMP-54F28), a Wnt signaling antagonist. The agency placed the hold in June after …

    Published on 9/4/2014
  • CLINICAL NEWS: Lilly's Peglispro superior to Lantus in Type I diabetics

    Eli Lilly and Co. (NYSE:LLY) said once-daily basal insulin peglispro (LY2605541) met the primary endpoint of non-inferiority to Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) in reducing HbA1c from …

    Published on 9/4/2014
  • CLINICAL NEWS: Antisense reports acromegaly data

    Antisense Therapeutics Ltd. (ASX:ANP) said 200 mg of ATL1103 twice-weekly met the primary endpoint in a 26-patient, open-label Phase II trial to treat acromegaly. That dosage reduced serum insulin-like growth factor-1 (…

    Published on 9/3/2014
  • CLINICAL NEWS: Edison's EPI-743 misses Rett syndrome endpoint

    Edison Pharmaceuticals Inc. (Mountain View, Calif.) said EPI-743 missed the primary endpoint of improving the Rett Syndrome Clinical Severity Scale score vs. placebo in a Phase II trial. The compound did meet a …

    Published on 9/3/2014
  • CLINICAL NEWS: Flexion provides FX006 update

    Flexion Therapeutics Inc. (NASDAQ:FLXN) said it now expects to complete Phase III development of FX006 to treat moderate to severe osteoarthritis (OA) knee pain by the end of 2015 -- a year earlier than the company had …

    Published on 9/3/2014
  • CLINICAL NEWS: Sanofi dengue vaccine meets Phase III endpoint

    Sanofi (Euronext:SAN; NYSE:SNY) said its dengue vaccine met the primary endpoint vs. placebo in a Phase III trial. The subcutaneous vaccine reduced symptomatic, virologically confirmed dengue fever cases by 60.8% vs. …

    Published on 9/3/2014
  • CLINICAL NEWS: Tetraphase up on Phase III cUTI data

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) was up $1.93 (15%) to $15.01 on Wednesday after reporting data from the lead-in portion of the Phase III IGNITE 2 trial of eravacycline to treat complicated urinary tract …

    Published on 9/3/2014
  • CLINICAL NEWS: Teva's reslizumab meets primary endpoint in asthma trials

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said IV reslizumab met the primary endpoint of reducing the frequency of clinical asthma exacerbations vs. placebo in two Phase III trials to treat severe eosinophilic …

    Published on 9/3/2014
  • CLINICAL NEWS: Detailed heart failure data disclosed for LCZ696

    LCZ696 from Novartis AG (NYSE:NVS; SIX:NOVN) led to a 20% reduction in risk on a composite of cardiovascular death or heart failure hospitalization, the primary endpoint, compared with enalapril in the 8,442-patient …

    Published on 9/2/2014
  • CLINICAL NEWS: Sanofi, Regeneron report detailed alirocumab data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) presented detailed data at the European Society of Cardiology meeting in Barcelona from four Phase III trials of subcutaneous …

    Published on 9/2/2014
  • CLINICAL NEWS: Stable CAD study shows no benefit with ivabradine

    Servier (Neuilly-sur-Seine, France) reported data from the SIGNIFY trial showing that its Procoralan ivabradine missed the primary endpoint of reducing the incidence of a composite of cardiovascular death or nonfatal …

    Published on 9/2/2014
  • CLINICAL NEWS: ZMapp reverses advanced Ebola in monkeys

    In a primate study, ZMapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.) reversed 100% of advanced Ebola cases. A research group led by Gary Kobinger of the University of Manitoba that included Mapp CEO Larry …

    Published on 8/29/2014
  • CLINICAL NEWS: FDA lifts partial hold on OncoMed's vantictumab

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said FDA lifted a partial hold on the company's Phase Ib trials of vantictumab (OMP-18R5), a human HuCAL mAb targeting the Wnt signaling pathway. The agency placed the hold …

    Published on 8/28/2014
  • CLINICAL NEWS: GSK/NIAID Ebola vaccine gets grant for trials

    The Wellcome Trust, the Medical Research Council and the U.K.'s Department for International Development provided a L2.8 million ($4.6 million) grant to fund trials of an Ebola vaccine candidate from GlaxoSmithKline plc…

    Published on 8/28/2014
  • CLINICAL NEWS: Repros jumps on Phase III Androxal data

    Repros Therapeutics Inc. (NASDAQ:RPRX) jumped $3.37 (19%) to $21.58 on Thursday after reporting data from the Phase III ZA-305 trial of Androxal enclomiphene to treat secondary hypogonadism. In the trial, 65.9% of …

    Published on 8/28/2014
  • CLINICAL NEWS: Kite flies on CAR T data

    Kite Pharma Inc. (NASDAQ:KITE) jumped $8.98 (40%) to $31.90 in early after-hours trading on Monday after the Journal of Clinical Oncology published updated data from a Phase I/II trial of KTE-C19 to treat advanced B …

    Published on 8/25/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993